Table 4 Multivariable regression odds ratios for chemotherapy recommendation following ODX testing
Variable | Odds Ratio (95% CI) | P-Value |
|---|---|---|
Year of Diagnosis | ||
2010 | Ref | Ref |
2011 | 0.87 (0.48–1.60) | 0.66 |
2012 | 0.65 (0.34–1.24) | 0.18 |
2013 | 0.73 (0.39–1.36) | 0.31 |
2014 | 0.66 (0.36–1.19) | 0.16 |
2015 | 0.44 (0.24–0.82) | < 0.01** |
2016 | 0.51 (0.27–0.96) | 0.04* |
Patient Age at Diagnosis (Years) | ||
< 50 | Ref | Ref |
50–59 | 0.73 (0.48–1.10) | 0.13 |
60–69 | 0.39 (0.25–0.61) | < 0.01** |
> 69 | 0.35 (0.18–0.66) | < 0.01** |
Grade | ||
I | Ref | Ref |
II | 1.73 (1.16–2.59) | < 0.01** |
III/IV | 3.55 (2.17–5.83) | < 0.01** |
Unknown | 2.61 (0.34–20.30) | 0.35 |
LN Status | ||
Negative | Ref | Ref |
Positive | 3.54 (2.29–5.46) | < 0.01** |
Unknown | 1.26 (0.39–4.08) | 0.69 |
Tumor Size (mm) | ||
0.1–19 | Ref | Ref |
20–39 | 1.51 (0.94–2.45) | 0.08 |
> 40 | 4.36 (1.98–9.62) | < 0.01** |
Unknown | 1.03 (0.18–6.05) | 0.98 |
Clinical Stage | ||
1 | Ref | Ref |
2 | 1.50 (0.90–2.50) | 0.11 |
3 / 4 | 2.72 (0.86–8.65) | 0.08 |
MD Clinical Experience (Years) | ||
< 10 | Ref | Ref |
10–19 | 1.89 (0.74–4.81) | 0.17 |
20–29 | 4.05 (1.57–10.43) | < 0.01** |
> 29 | 4.48 (1.68–11.95) | < 0.01** |
MD Gender | ||
Female | Ref | Ref |
Male | 0.50 (0.34–0.74) | < 0.01** |
Patient Volume | 1.01 (1.01–1.03) | 0.04* |
Average Patient Age | ||
< 65 Years | Ref | Ref |
> 65 Years | 0.72 (0.34–1.56) | 0.40 |
ODX RS Classification | ||
Low | Ref | Ref |
Intermediate | 12.30 (8.70–17.38) | < 0.01** |
High | 233.08 (95.40–569.42) | < 0.01** |